Sun Pharma Advanced Research Company (SPARC) has announced that its licensee has received an approval from the Drug Controller General of India for Paclitaxel Injection Concentrate for Nanodispersion (PICN), indicated for the treatment of metastatic breast cancer.
In a clinical study in metastatic breast cancer patients, PICN was found to be equally effective and safe when compared to ABRAXANE. PICN is approved in India for 260 mg/m2 and 295 mg/m2 doses to be administered every 3 weeks.
PICN is a novel formulation of Paclitaxel using SPARC's proprietary Nanotecton platform technology and is a Cremophor and Albumin free formulation. It offers the convenience of a quick and easy one-step dilution and infusion preparation for healthcare professionals.
Shares of the company gained Rs 3.15, or 1.96%, to trade at Rs 164. The total volume of shares traded was 140,857 at the BSE (9.28 a.m., Friday).